MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nifedipine

CAS No. : 21829-25-4

MCE 站：Nifedipine

产品活性：Nifedipine (BAY-a-1040) 是有效的钙离子通道 (calcium channel) 阻滞剂，常用于心肌功能不全的相关研究。

研究领域：Membrane Transporter/Ion Channel  |  Neuronal Signaling  |  Autophagy

作用靶点：Calcium Channel  |  Autophagy

In Vitro: Nifedipine (BAY-a-1040) (100 μM) significantly lowers the viability of the WKPT-0293 Cl.2 Cells, and treatment of nifedipine (10 or 100 μM) plus FAC induces a significant reduction in cell viability, but there are no significant differences in viability between the control cells and the cells treated with 100 μM of FAC or 1 and 10 μM of nifedipine.Nifedipine (BAY-a-1040) (1, 10, or 100 μM) significantly increases iron level in WKPT-0293 Cl.2 cells. Nifedipine treatment also increases expression of TfR1, DMT1+IRE and DMT1-IRE in WKPT-0293 Cl.2 cells. In addition, co-treatment with nifedipine (100 μM) and FAC (100 μM) increases TfR1, DMT1+IRE and DMT1-IRE expression in WKPT-0293 Cl.2 cells. Nifedipine plus ritodrine produces a significantly greater inhibition of contractility than each drug alone in the midrange of concentrations. The combination of nifedipine plus nitroglycerin or nifedipine plus atosiban produces a significantly greater inhibition than nitroglycerin or atosiban alone but not greater than nifedipine. The combination of nifedipine plus NS-1619 (Ca²⁺-activated K⁺ [BKCa] channel opener) reduces the inhibitory effect of each drug. Nifedipine (BAY-a-1040) (2 μM) significantly inhibits P. capsici mycelial growth and sporulation. Nifedipine (BAY-a-1040)-induced inhibition of mycelial growth is calcium-dependent. Nifedipine (0.5 μM) increases P. capsici sensitivity to H₂O₂ in a calcium-dependent manner. Nifedipine inhibition of P. capsici virulence and expression of genes involved in pathogenicity.

In Vivo: In Nifedipine (BAY-a-1040) (50 mg/kg)- and CsA-treated rats, the BL dimensions (BLi and BLk), MD dimensions (MDk) and vertical dimensions (VHi and VHk) are significantly increased (P < 0.05) at the end of the 4th week.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Neuroprotective Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Ionomycin  |  L-Ascorbic acid  |  Thapsigargin  |  Verapamil hydrochloride  |  Ebselen  |  Fasudil Hydrochloride  |  2-Aminoethyl diphenylborinate  |  Acetylcholine chloride  |  GSK1016790A  |  Tetrandrine  |  Mibefradil dihydrochloride  |  CDN1163  |  Nimodipine  |  Gabapentin  |  L-Phenylalanine  |  Penfluridol  |  Diltiazem hydrochloride  |  Istaroxime hydrochloride  |  Cromolyn sodium  |  GSK-7975A  |  (S)-(-)-Bay-K-8644  |  Ethacrynic acid  |  Felodipine  |  Cilnidipine  |  Amlodipine  |  Ru360  |  DS16570511  |  Ranolazine dihydrochloride

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。